Scientists say they've developed a way to pinpoint risk of developing acute myeloid leukemia years before the onset of symptoms, according to a report in the journal Nature. The researchers sequenced DNA from the blood of 124 patients with AML and 676 people who did not have AML or a related cancer, evaluated data from AML-associated genes, and found certain mutations were more common in those who developed AML.
Mutations could detect AML risk years before symptoms start, scientists say
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.